SNO Storm: Phase 3 Results for DCVax-L

Highlights from the Society for Neuro-Oncology (SNO) 2022 Annual Meeting

DCVax-L (Northwest Biotherapeutics) and other immunotherapies directed at brain cancers have made steady clinical progress over the past decade. A new paper was just published summarizing the Phase 3 results for DCVax-L.

While the road has often been bumpy, much has been learned, and the pace of progress is accelerating. We plan to post more about the most promising new approaches in brain cancer immunotherapies over the coming months.

There is no doubt that immunotherapies will be critical to the assembly of a Brain Cancer Tool Box to treat patients with various adult and pediatric brain cancers. For Team Julie, a sophisticated immuno-oncology combination protocol was developed to attack GBM. The latest MRI scans were very exciting.